U.S. FDA approves Cangene's anti-hepatitis B product
01-Feb-2006
Cangene manufactures HepaGam B(TM) in its Winnipeg facility using a process similar to that of WinRho(R) SDF and Vaccinia immune globulin, the Company's earlier FDA-approved drugs. The Company anticipates that the drug will be distributed in the U.S. by Apotex Corp., a member of the Apotex Group, Cangene's majority shareholder. The companies expect to launch the product within the next few months.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
SPECK Pumpen Verkaufsgesellschaft GmbH - Neunkirchen am Sand, Germany
Go to page
Study finds mechanism that turns white fat into energy-burning brown fat - Raises hopes for new obesity and diabetes treatments
Go to page
Sir Gregory Winter joins Covagen’s Scientific Advisory Board
Go to page
How a “date” between immune cells makes rheumatism disappear - Major success: New approach for treating autoimmune diseases
Go to page